Skip to content

Earnings call

Indoco Remedies Q4 FY26 earnings call

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Indoco's Plant-1 in Goa supplies solid oral products to the US and could not supply to optimum requirement during a major part of the master manufacturing cycle in the same quarter last year. Indoco's standalone net revenues in Q4 FY '26 were INR 4,291 million, compared with INR 3,411 million in the same quarter last year and INR 3,896 million in Q3 FY '26, representing growth of 25.8% and 10.1%, respectively. The market had less than 30 days of Cital stock, according to a Pharmarack review. Indoco directly and indirectly reaches around 1,50,000 chemists through Warren Remedies, its OTC arm, and its prescription business. Indoco's consolidated total loan position was about 960, with long-term loans of INR 620 crore and short-term loans of INR 344 crore, and remained more or less the same as in March '25.

The numbers management gave

Results

  • Indoco's standalone net revenues in Q4 FY '26 were INR 4,291 million, compared with INR 3,411 million in the same quarter last year and INR 3,896 million in Q3 FY '26, representing growth of 25.8% and 10.1%, respectively.
    Show source
    Let me first begin with the business highlights: Standalone net revenues in the company for the 4th Quarter FY '25-'26 are at INR 4,291 million compared to INR 3,411 million for the same quarter last year and INR 3,896 million for the immediately preceding quarter, that is Q3 FY '26 growing at 25.8% and 10.1% growth respectively.
  • Indoco's consolidated net revenues in Q4 FY '26 were INR 4,559 million, compared with INR 3,839 million in the same quarter last year and INR 4,343 million in Q3 FY '26, representing growth of 18.8% and 5%, respectively.
    Show source
    Consolidated net revenues of the company for the 4th Quarter are at INR 4,559 million compared to INR 3,839 million for the same quarter last year and INR 4,343 million for the immediately preceding quarter with 18.8% and 5% growth respectively.
  • Indoco's standalone EBITDA to net sales in Q4 FY '26 was 14.7%, or INR 630 million, compared with 1%, or INR 35 million, in the same quarter last year.
    Show source
    Standalone EBITDA to net sales for the quarter is 14.7% at INR 630 million compared to 1% at INR 35 million.
  • Indoco's standalone EBITDA in Q3 FY '26 was 6.6%, or INR 259 million.
    Show source
    And for immediately preceding quarter, EBITDA was 6.6% at INR 259 million.
  • Indoco's consolidated EBITDA to net sales in Q4 FY '26 was 10.9%, or INR 497 million, compared with minus 0.2%, or negative 8 million, in the same quarter last year.
    Show source
    Consolidated EBITDA to net sales for the quarter is 10.9% at INR 497 million compared to Page 3 of 17 Indoco Remedies Limited May 07, 2026 minus 0.2% at negative 8 million last year.
  • Indoco's consolidated EBITDA in Q3 FY '26 was 7.3%, or 315 million.
    Show source
    And for the immediately preceding quarter 7.3% at 315 million.
Show 27 more statements

Results

  • Indoco's domestic formulation business revenue in Q4 FY '26 was INR 1,739 million, compared with INR 1,851 million in the same quarter last year.
    Show source
    Revenues from domestic formulation business for the quarter are at INR 1,739 million as compared to INR 1,851 million.
  • Indoco's vitamins, anti-diabetics, stomatology, gastrointestinal and cardiac therapeutic segments performed well in Q4 FY '26 compared with the same quarter last year.
    Show source
    Major therapeutic segments like vitamins, anti-diabetics, stomatology, gastrointestinal and cardiac performed well during the quarter as compared to the same quarter last year.
  • Indoco's international formulation business revenue in Q4 FY '26 grew by 94.6% to INR 2,147 million, compared with INR 1,104 million in the same quarter last year.
    Show source
    Revenues from international formulation business grew by 94.6% at INR 2,147 million compared to INR 1,104 million.
  • Indoco's regulated-markets revenue in Q4 FY '26 grew by 78.3% to INR 1,401 million, compared with INR 785 million in the same quarter last year.
    Show source
    Revenues from reg markets for the quarter grew by 78.3% at INR 1,401 million against INR 785 million.
  • Indoco's US business revenue in Q4 FY '26 grew by 77.5% to INR 546 million, compared with INR 308 million in the same quarter last year.
    Show source
    Revenues from US business for the quarter grew by 77.5% at INR 546 million as against INR 308 million.
  • Indoco's Europe revenue in Q4 FY '26 grew by 68.7% to INR 786 million, compared with INR 466 million in the same quarter last year.
    Show source
    Revenues from Europe for the quarter grew by 68.7% at INR 786 million as against INR 466 million.
  • Indoco's revenue from South Africa, Australia and New Zealand in Q4 FY '26 was INR 692 million, compared with INR 122 million in the same quarter last year; the base was small.
    Show source
    And for South Africa, Australia and New Zealand the quarter grew by, the base being small, the revenues were at INR 692 million as against INR 122 million.
  • Indoco's emerging-markets revenue in Q4 FY '26 grew by 134% to INR 746 million, compared with INR 318 million in the same quarter last year.
    Show source
    Revenues from emerging markets for the quarter grew by 134% at INR 746 million as against INR 318 million.
  • Indoco's API business revenue in Q4 FY '26 declined by 23% to INR 315 million, compared with INR 409 million in the same quarter last year.
    Show source
    Revenues from API business for the quarter de -grew by 23% at INR 315 million as against INR 409 million.
  • AnaCipher CRO and Indoco Analytical Solutions services revenue in Q4 FY '26 grew by 65.3% to INR 895 million, compared with INR 467 million in the same quarter last year.
    Show source
    And the services part AnaCipher CRO and Indoco Analytical Solutions for the quarter grew by 65.3% at INR 895 million as against INR 467 million.
  • Indoco said emerging-market growth in Q4 FY '26 was a primary reason the number of days of receivables was increasing, because emerging markets have longer receivables than domestic business and API business.
    Show source
    So, that is the primary reason of receivables, which are number of days of receivables, which are going up.
  • Cital's internal performance in Q4 FY '26 was down 10% for the quarter and down 1% quarter-on-quarter, while it was growing in IQVIA.
    Show source
    So, Cital, if you look at internal performance, for the quarter it is down 10% and QoQ, it is down 1%, but in IQVIA, it is growing.
  • Indoco's India ophthalmic division recorded INR 37 crores in primary-level internal sales for the year.
    Show source
    At primary level for internal sales, for the year we have clocked INR 37 crores in India.
  • Indoco's foreign-currency exchange gain was INR 16 crore in other operating revenue.
    Show source
    Maulik: No, in the exceptional… Sundeep Bambolkar: If you are referring to other operating revenue then it is INR 16 crore exchange gain on the foreign currency.
  • Indoco corrected its exceptional income figure to INR 3.7 crores.
    Show source
    My mistake, it is INR 3.7 crores.
  • The business grew from 90 or 92 or 94 last year to 130 this year.
    Show source
    130 this year.
  • New launches contributed more than INR 2 crore in the 4th Quarter and INR 20 crore in the financial year.
    Show source
    In the financial year INR 20 crore and we are getting a sizable amount in new launches and they are doing very well.
  • FPP was impacted by almost INR 4 crore of extraordinary costs taken at the end of Q4 on expired products, as well as product mix.
    Show source
    Almost INR 4 crore was the impact seen, but also the product mix.
  • FPP's cost of goods sold on Q4 sales was extraordinarily high because some products in Indoco Remedies' market have poor margins, and selling more of them or making shelf stock adjustments causes a hit in that quarter.
    Show source
    So, we actually looked into this because the COGS on the Q4 sales of FPP have been extraordinarily high because some of our products are not…We do have a few products in our market which don't get very good margins and when we se ll more Page 15 of 17 Indoco Remedies Limited May 07, 2026 of that or when we have to do a shelf stock adjustment or things like that, in that quarter you see a hit.

Money and capital

  • Indoco's consolidated total loan position was about 960, with long-term loans of INR 620 crore and short-term loans of INR 344 crore, and remained more or less the same as in March '25.
    Show source
    We are at total consolidation level, we are at 960 odd number.
  • IRL alone has INR 630 crore debt combined, and the total entity has close to 950 debt.
    Show source
    Aditi Panandikar: So, as we said in IRL alone there is INR 630 crore debt which is combined and for the total entity it is close to 950.
  • Around INR 140 crore of Indoco Remedies' short-term debt is to be repaid in the coming year.
    Show source
    Of all this our short term debt which has to be repaid will be around INR 300 crore.140 for the next year So, INR 140 crore to be repaid in the next year, coming year.
  • The company has a commitment to repay INR 140 crore in financial year '26-'27, another 140 in the year after that, and almost a similar amount in '28-'29.
    Show source
    Another 140 in a year after that and almost similar amount after in '28-'29 So, about INR 140 crore every year for next 3 years.
  • Indoco Remedies' target is to repay or prepay a little more than INR 140 crore each year for the next 3 years.
    Show source
    Our target will be to repay or to prepay a little more than this.
  • Indoco Remedies' interest rate is in the range of 8.5 to 9, and the company said the repayment of 140 could be considered as a reduction in overall interest cost.
    Show source
    Page 16 of 17 Indoco Remedies Limited May 07, 2026 Pramod Ghorpade: So, Mr. Madhav, if you see our repayment schedule, 140 as I mentioned, and our average interest rate is in the range of 8.5 to 9, so you can consider that much reduction in overall interest cost.
  • A repayment of 140 would mean around INR 120 crores reduction, according to Madhav's calculation.
    Show source
    Madhav: Okay, so then, so the 960 minus 140 means, around INR 120 crores reduction will be there.
  • Considering INR 140 crore repayment in a staggered manner, the average cost of borrowing is just short of 9%.
    Show source
    Sundeep Bambolkar: Yes, 140 crore repayment if you consider in a staggered manner, then the average cost of borrowing is just short of 9%.

What it is building and selling

Projects and capacity

  • Indoco's Plant-1 in Goa supplies solid oral products to the US and could not supply to optimum requirement during a major part of the master manufacturing cycle in the same quarter last year.
    Show source
    Plant-1 in Goa in particular supplies solid oils to U.S. and this plant therefore had got impacted as in we could not supply it to optimum requirement.
  • Warren Remedies has installed only 1 of the 4 lines provided for at its toothpaste block.
    Show source
    So, all the provision was made, we have installed only 1.
  • Warren Remedies' toothpaste block can make 5,000 kg batches with only 5 people inside.
    Show source
    So, capacity utilization of the toothpaste block is not a very big concern for us because we have set up a state-of-art unit and we are able to make 5,000 kg batches with only 5 people inside.
  • Warren Remedies has not installed a second mouthwash line because Indoco Remedies continues to make mouthwashes at other locations.
    Show source
    There was a second line of mouthwashes but we have not gone for that yet because we continue to make mouthwashes at other locations.

Demand and pricing

  • The market had less than 30 days of Cital stock, according to a Pharmarack review.
    Show source
    And the other day, I had a Pharmarack review where they disclosed that in the market, there is less than 30 days stock of this product.
  • Indoco was the 13th player in the ophthalmic market, where Entod and Sunways had a lead because ophthalmics were fundamentally core areas of business for them.
    Show source
    And we have to recognize that we are the 13 th player in this market where companies like Entod, Sunways, even very small organizations are able to get a lead on us.
Show 8 more statements

Demand and pricing

  • Cital prescriptions were growing.
    Show source
    And so are prescriptions on it.

Segments

  • Indoco directly and indirectly reaches around 1,50,000 chemists through Warren Remedies, its OTC arm, and its prescription business.
    Show source
    Directly and indirectly, our organization reaches around 1,50,000 chemists.
  • Cyclopam is available at 3.5 lakh chemists.
    Show source
    However, if you look at availability of Cyclopam, it is available at 3.5 lakh chemists.
  • Indoco's sterile products were INR 12 crores, and the rest of the products were oral solids.
    Show source
    Sterile is INR 12 crores and the rest is all oral solids.
  • Sensodent DSP and DPC have been well received, and the first consignment has gone into the market; Indoco Remedies is looking for additional orders.
    Show source
    The first consignment which has gone into the market and I think we are now looking for additional orders Page 11 of 17 Indoco Remedies Limited May 07, 2026 and as such the division looks set to continue to grow.
  • The company launched Cyclopam AC suspension and Astrotel in this quarter.
    Show source
    The latest product which we have launched in this quarter is Cyclopam AC suspension, there is also Astrotel.
  • Indoco's OTC business has done well, and the company is working to add product presence with grocers, modern trade and quick commerce. Replaced by a later filing.
    Show source
    The OTC business has also done well and our efforts to add presence of our products with the grocers, the modern trade and quick commerce are underway and should soon give promising results as well.

Deals and partners

  • Warren Remedies has started exporting toothpaste from its site to South Africa; exports amounted to 37 lakhs as a small amount to start with, and the company is seeking other such opportunities.
    Show source
    37 lakhs a small amount to start with and we are seeking other such opportunities.

Risks, rules and outside factors

Outside factors

  • Indoco said macroeconomic factors were not conducive to business, particularly regarding cost of goods and likely disruption in exports.
    Show source
    The macroeconomic factors at this time are certainly not at all conducive for doing business, especially as regards the cost of goods and the likely disruption in exports.

Everything else said on the call

What management stressed

  • The company has close to 350 people in the field and needs to add more products to the market to justify that field force.
    Show source
    Of course, we need to add more products to the market in order to justify because we have close to 350 people in the field.
  • Indoco has tight control on CAPEX and is making efforts to bring down operating expense going forward. Replaced by a later filing.
    Show source
    Aditi Panandikar: Yes, additionally, as we have disclosed earlier, there is very tight control on CAPEX now and good effort is going on to bring down the operating expense also going forward.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Sajal Kapoor: Hi, thanks for the opportunity. The performance is definitely a recovery sequentially for sure and that is heartening to note. I have a couple of questions around the receivables and the debt if I may. The standalone trade receivables grew 45% while revenues grew only about 9% and Q4 alone saw a disproportionate spike. So, can you break down the receivables aging and identify which geographies or channels are driving the elongation of collection concerns and confirm what percentage of Q4 revenue was kind of recognized on shipment versus actual receipt because it's kind of looking slightly disturbing and the interest payments and the debt. So, both the working capital, receivabl

    Answer, aditi panandikar

    Aditi Panandikar: So, I will quickly answer your question. And then Pramod will probably give you more details. For this quarter in particular, what you would have seen is that the international business has done so well and typically our collections for international business, especially collections for the emerging market international business, have a long credit period. So, that has probably Page 4 of 17 Indoco Remedies Limited May 07, 2026 impacted. Coming back to the borrowings and happy to share that efforts are underway to ensure that the borrowings get reduced at the earliest. And with performance improving, I'm sure we will be able to do that. But I will allow Pramod to give you answers on some of your concerns.

    Answer, pramod ghorpade

    Pramod Ghorpade: So, Mr. Sajal, as Madam mentioned, specifically about the receivables, you're right. Our 4th Quarter performance, if you see, in terms of exports to reg market, which is overall up by close to about 28%-29%. Out of that, emerging market growth is about -- significant growth, I would say, in a 4th Quarter, where we have longer receivables, I would say, as compared to domestic business and API business. So, that is the primary reason of receivables, which are number of days of receivables, which are going up. Your second question about the overall loan position, that remains more or less same, as compared to last year, March '25. We are at total consolidation level, we are at 960 odd number. Long term, INR 620 crore and short term of INR 344 crore.

    Answer, pramod ghorpade

    More or less that was the same position during last year. In between, whatever repayment commitment was there with the funders, banks, which we have repaid along with interest, plus additional borrowing in some pockets initially during six months for our CAPEX. But of course, we are very sure in terms of servicing the debt along with interest, with you know, EBITDA number, which we would like to maintain during next four quarters. Thank you.

    Answer, aditi panandikar

    Aditi Panandikar: Yes, additionally, as we have disclosed earlier, there is very tight control on CAPEX now and good effort is going on to bring down the operating expense also going forward. This should all help.

  2. Question

    Sajal Kapoor: Sure, ma'am. And just one follow-up. Can you help me double-click on supplier payables and the MSME dues because they have risen sharply?

    Answer, aditi panandikar

    Aditi Panandikar: Yes, there has been some, where we have not paid suppliers on time given some of the cash flow situation we had. But I am confident within a week we should be able to settle this.

  3. Question

    Sajal Kapoor: All right. Okay. Thank you so much. I will rejoin the queue.

    Answer, aditi panandikar

    So, typically the numbers you see in IQVIA or any of the agencies like Pharmarack on our product is what we consider secondary, that is what is sold from stockist to retailer. And then the number of prescriptions we generate, we use it as a measure to understand demand for our products and therefore the absolute offtake at the chemist counter, which is tertiary. So, if you look at, first of all, what we call primary, which is the booking of sales, that for the quarter ended March is often dependent on the motivation morale and how many people in your field, staff are actually going to do their annual target. And they start going a little low, despite of all efforts from our side. We always see this kind of a performance. I will give you an example for, let's take the category of, I mean, if we take stomatologicals itself, then as per IQVIA, we are down only by 8%, but my primaries are down 20%. And then if you look at the prescriptions on those products, they are all in high growth.

    Answer, aditi panandikar

    What it simply means is that if you are seeing an Rx performance now, then your IQVIA should follow after that and unless there is too much stock in the market, your primary should automatically get corrected. However, your concern about if we are really generating demand, what if our products are getting either substituted or not available? For that, this year, in particular, we are undertaking a major exercise to reach out to the stockists who stock our products and the retailers. I can give you some statistics. Directly and indirectly, our organization reaches around 1,50,000 chemists. That is both through Warren Remedies, which is the OTC arm, and our own prescription business. However, if you look at availability of Cyclopam, it is available at 3.5 lakh chemists.

    Answer, aditi panandikar

    So, generally, it is prescriptions and demand created which is expected to make your product available. That is how we work. But typically, because our products are seasonal, what always happens is, when the season doesn't come in, you see the stockist is not very motivated to increase the inventory he carries on certain products and therefore, he goes muted. Down the line, there are very few shortages because there are stocks in market. Let's take our product, Cital, for example. It is a urinary alkalizer and typically does very well in summers. But this year, in the month of March, I think there were a few rains also and summer did not kick in the way it should have.

    Answer, aditi panandikar

    So, Cital, if you look at internal performance, for the quarter it is down 10% and QoQ, it is down 1%, but in IQVIA, it is growing. And so are prescriptions on it. And the other day, I had a Pharmarack review where they disclosed that in the market, there is less than 30 days stock of this product. So, typically now, Cital should fire. But these are not things we can always control because always motivating the stockist to purchase from us pretty much depends on a lot of many factors including the morale of the field staff who are going to do their annual target. I hope that answers your question. Nirmam: Yes, ma'am.

    Answer, aditi panandikar

    We tried to create two divisions. We were very bullish on it because as you know, we have filed several ophthalmic ANDAs in U.S. So, as a therapy, it remains an area of attention for us. But in India, for the last four years, we were not able to grow the business too much and it remained very much dependent on whether conjunctivitis came in o r not and things like that. And at the size at which it was, we could not give it enough attention. So, that is why the hang off. Other than this, if you look at the present portfolio we hold, most of it is coming within the 4 or 5 main segments of the company. So, you will have products either in respiratory, anti - infective, stomatological, GI or vitamins and minerals which is carried by a Gynaec division.

    Answer, aditi panandikar

    At this point, I don't see any more such identified opportunities for the Ind ia business. Nirmam: And just to confirm, so this division split was also not done to tide over the liquidity situation, right, because… Aditi Panandikar: Absolutely not.

    Answer, aditi panandikar

    It is a very small division. At primary level for internal sales, for the year we have clocked INR 37 crores in India. And we have to recognize that we are the 13 th player in this market where companies like Entod, Sunways, even very small organizations are able to get a lead on us. Obviously, because for them it is a very, very fundamentally core area of business. So, they approach it differently. Nirmam: Okay, understood. Coming to our international business, we have seen good growth across all the markets, U.S., Europe.

    Answer, aditi panandikar

    Aditi Panandikar: So, what we have done, which I have said on earlier calls, is for our key products we have gone into adding second sites. So, some of the sterile sales for U.S. that you see in this quarter have actually got billed from those sites and that has helped. So, therefore, what will really impact us if the plant situation doesn't get resolved really is the future approvals which should be coming on time. But otherwise we are okay. Of course, we carry and continue to spend a lot on that site. So, that is an area of concern and we are trying to resolve that as soon as possible. But other than that, U.S. today is not just sterile and ophthalmic.

    Answer, aditi panandikar

    We do a considerable amount of solid orals and now we are getting into liquid orals as well. Also the U.K. and Europe business has done very well. And we have a decent order book right now and I am sure our team will work very hard to continue this kind of performance. Nirmam: Sure. So, one question on the interest cost for this quarter. So, if you look at the consolidated numbers, the interest cost has gone up materially. So, is there some forex impact also here?

    Answer, aditi panandikar

    Therefore it comes in the consolidations. Because there was one loan in foreign currency and as such it is notional unless the war goes on and on and on. Then it will actually impact us. But maybe Pramod would like to say something.

    Answer, pramod ghorpade

    Pramod Ghorpade: So, this quarter exchange loss itself on a foreign currency loan, ECB loan is substantial. Almost half a portion of this finance cost is towards the exchange. Nirmam: So, INR 20 crore impact?

  4. Question

    Kenil Mehta: Ma'am, I had one question. Last quarter we had a loss of INR 34 crores. We had a net worth negative of INR 34 crores. This quarter it is INR 82 crores. Any reason why FPP which has seen increase in sales from INR 35 crores to INR 48 crores has seen a negative net worth of INR 50 crores in this quarter increase?

    Answer, pramod ghorpade

    Pramod Ghorpade: So, Kenil, as you know, for FPP it is early years. It's all about investment. So, the negative net worth which you see is the losses incurred during last couple of years. And we expect now this to turn around in coming years. But the net worth which you are referring is the impact of the losses incurred since acquisition till today.

  5. Question

    Kenil Mehta: No, no. The last quarter as per your result, press release, it was INR 25 crores negative net worth. This quarter it is INR 82 crores. So, what is the reason for INR 50 crores jump in a quarter?

    Answer, aditi panandikar

    Aditi Panandikar: Yes, so Kenil, if you look at, as you know, FPP had a historical business of purchase and sale from others. And it typically depends on the portfolio of FPP in that particular quarter. So, whenever FPP only sells products supplied by Indoco, we do much better. But when they are purchasing finished goods from others and selling, that margin comes down. So, if you look at sale of FPP and the COGS, that is where you will see the maximum jump. Page 8 of 17 Indoco Remedies Limited May 07, 2026 Pramod Ghorpade: Now Kenil, you are looking at consolidated number which includes not only FPP but Warren also, another legal entity.

    Answer, pramod ghorpade

    There also we have negative number. So, that is both put together, not only FPP but FPP plus Warren. Kenil Mehta: Okay, so you have not specified the Warren part in that press release.

    Answer, aditi panandikar

    Aditi Panandikar: Warren as you know is an OTC business and we have very clearly decided that for at least 3 years we will consistently support it for advertising and any other things required to build that business.

  6. Question

    Kenil Mehta: Understood. And ma'am, we had sold a lot of products in Europe market, we see, based on product basket in 2025 and 2026. But based on your export data, we are not seeing that expansion in that product basket except for allopurinol and paracetamol and colchicine, few products.

    Answer, aditi panandikar

    Aditi Panandikar: Okay, so what happens is, as you know, Europe and U.K., there is major fluctuation in pricing. So, sometimes some of these small molecules, if the current business environment doesn't support in a manner that we should make margin on it, then we choose not to sell. Sundeep would like to say something.

    Answer, sundeep bambolkar

    Sundeep Bambolkar: See, besides allopurinol and what you mentioned, colchicine, we are also selling pregabalin and zonisamide very well, these two molecules. So, with contract manufacturers, of course there is cetirizine, there is paracetamol, zonisamide, pregabalin, colchicine. So, there are many products. We are not dependent on one or two.

  7. Question

    Kenil Mehta: But we have got a lot of approvals, like apixaban, 27:09 rivaroxaban and ecosmide.

    Answer, aditi panandikar

    Aditi Panandikar: Apixaban should come in soon.

  8. Question

    Kenil Mehta: Okay, understood, And on the API business side, as we have got approval for the Warren Remedies part, should we see the increased scale-up now for that part of business too, for outside consumption?

    Answer, aditi panandikar

    Aditi Panandikar: Yes, so Warren Remedies doesn't yet have a reg market approval. So, till now, it makes key starting materials for us, which we finish in Patalganga and sell in the reg markets. Therefore, Warren Remedies actually carries, we are not able to optimize it fully because what is made at Warren Remedies does not fetch reg market prices as of now.

  9. Question

    Kenil Mehta: Understood.

    Answer, aditi panandikar

    Aditi Panandikar: And that is partly the reason Warren Remedies financials also get disturbed. Page 9 of 17 Indoco Remedies Limited May 07, 2026 Kenil Mehta: Understood.

  10. Question

    And I wanted to know any reason why we have got approval for 28:13 rivaroxaban but only we have supplied very negligible compared to other peers or captured the market share over last six months for U.S. market?

    Answer, pramod ghorpade

    Pramod Ghorpade: We have got approval only for one strength.

Show 4 more questions
  1. Question

    Kenil Mehta: Okay. Understood. No problem. Thank you.

    Answer, aditi panandikar

    Aditi Panandikar: So, same quarter last year in particular, if you remember, we were undergoing a major part of our master manufacturing cycle at two of our large solid oral sites, Plant-1 in Goa and Baddi 3. Plant-1 in Goa in particular supplies solid oils to U.S. and this plant therefore had got impacted as in we could not supply it to optimum requirement. And it is not just ophthalmics but we also have a considerable amount of solids coming as well as ophthalmics. Sterile is INR 12 crores and the rest is all oral solids.

    Answer, sundeep bambolkar

    Sundeep Bambolkar: We have got quite a basket of solid orals.

    Answer, pramod ghorpade

    Pramod Ghorpade: No, you are talking about other income? Maulik: No, in the exceptional… Sundeep Bambolkar: If you are referring to other operating revenue then it is INR 16 crore exchange gain on the foreign currency.

    Answer, aditi panandikar

    Aditi Panandikar: INR 34 crore exceptional income is not there. We got the number wrong. Page 10 of 17 Indoco Remedies Limited May 07, 2026 Maulik: Sorry, ma'am. My mistake, it is INR 3.7 crores.

    Answer, aditi panandikar

    Aditi Panandikar: Yes, It was lying idle for the longest time. Nirmam: Okay. Secondly, so in the cash flow statement I could see some provisions for doubtful debt and that has increased year-on-year. So, about INR 10 crores this year. So, is this in line with what we generally do or there is some issue?

    Answer, aditi panandikar

    Aditi Panandikar: So, the business has I think grown from 90 or 92 or 94 last year to 120. 130 this year. So, that is a good jump. All our key brands Sensodent K, KF, Kidodent as well as the new launches DSP and DPC of the Sensodent family. The Sensodent DSP, DPC has been well received. The first consignment which has gone into the market and I think we are now looking for additional orders Page 11 of 17 Indoco Remedies Limited May 07, 2026 and as such the division looks set to continue to grow. Of course, we need to add more products to the market in order to justify because we have close to 350 people in the field.

    Answer, aditi panandikar

    Aditi Panandikar: So, as we said in IRL alone there is INR 630 crore debt which is combined and for the total entity it is close to 950. Of all this our short term debt which has to be repaid will be around INR 300 crore.140 for the next year So, INR 140 crore to be repaid in the next year, coming year. Madhav: So, during the financial year 2027 is there any plan for any reduction, ma'am?

    Answer, pramod ghorpade

    Pramod Ghorpade: So, Mr. Madhav so, next financial year which is '26-'27 we have a commitment to repay 140. Another 140 in a year after that and almost similar amount after in '28-'29 So, about INR 140 crore every year for next 3 years. Our target will be to repay or to prepay a little more than this. Madhav: Okay, is there any additional CAPEX than the normal CAPEX? Are we planning for any CAPEX expenditure kind of thing in the current year or next year?

    Answer, aditi panandikar

    I think 4th Quarter total new launch has contributed to more than INR 2 crore. In the financial year INR 20 crore and we are getting a sizable amount in new launches and they are doing very well. So, products like Cital-PM6, Dropizin, Drotitec M, then we have we have Nosic-OD, OH-D3, we have Vepan CV, Vopanza, lot of new products as well as brand extensions being launched. The latest product which we have launched in this quarter is Cyclopam AC suspension, there is also Astrotel. All our new products are being doing pretty well. So, on that front I think… Madhav: If you can add this thing in the management presentation that will helps us lot.

  2. Question

    Kenil Mehta: Ma'am, I would like to know what is the capacity utilization for oral business at Warren Remedies out of the 4 lines? And what are the initiatives we are taking to increase our sales, other than OTC, export or contract manufacturing for some bigger players?

    Answer, aditi panandikar

    Aditi Panandikar: Thank you for that question because we have started exports from that site at this stage to South Africa, manufacture of toothpaste. I don't know whether it will come in this quarter, yes, it is. 37 lakhs a small amount to start with and we are seeking other such opportunities. Meanwhile, about 4 lines you said know, we have actually installed only 1. So, all the provision was made, we have installed only 1. There was a second line of mouthwashes but we have not gone for that yet because we continue to make mouthwashes at other locations. So, capacity utilization of the toothpaste block is not a very big concern for us because we have set up a state-of-art unit and we are able to make 5,000 kg batches with only 5 people inside.

  3. Question

    Kenil Mehta: Understood and what will be the actual revenue base you will see growing for the India business apart from the OTC in line with IPM or it will degrow over the last year that we are seeing.

    Answer, aditi panandikar

    Aditi Panandikar: FPP as Pramod explained, we were impacted with some extraordinary costs which were taken at end of this quarter on expired products etc. which is why it has seen a hit. Almost INR 4 crore was the impact seen, but also the product mix. So, we actually looked into this because the COGS on the Q4 sales of FPP have been extraordinarily high because some of our products are not…We do have a few products in our market which don't get very good margins and when we se ll more Page 15 of 17 Indoco Remedies Limited May 07, 2026 of that or when we have to do a shelf stock adjustment or things like that, in that quarter you see a hit.

  4. Question

    Kenil Mehta: Okay, understood. No questions. All the best.

    Answer, aditi panandikar

    Aditi Panandikar: For the year it is 120, I think this quarter it is INR 27.4 crores. Madhav: Okay, and so what is the plan for, I mean so how much reduction in interest expenses can be considered for both standalone and consolidated for the current financial year, madam? Page 16 of 17 Indoco Remedies Limited May 07, 2026 Pramod Ghorpade: So, Mr. Madhav, if you see our repayment schedule, 140 as I mentioned, and our average interest rate is in the range of 8.5 to 9, so you can consider that much reduction in overall interest cost.

    Answer, pramod ghorpade

    Madhav: Okay, so then, so the 960 minus 140 means, around INR 120 crores reduction will be there.

    Answer, sundeep bambolkar

    Sundeep Bambolkar: Yes, 140 crore repayment if you consider in a staggered manner, then the average cost of borrowing is just short of 9%. Madhav: Understood. Thank you very much.

Questions about this call

When was the Indoco Remedies Q4 FY26 earnings call transcript filed?
Indoco Remedies filed the transcript with the exchange on 11 May 2026. This page is built from that transcript.
What does this page list?
50 statements from the transcript across 8 topics, 42 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 14 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Indoco Remedies Q4 FY26 concall: what the company said · DalalOS